Two cancer drivers, one targetable pathway.

#FOXM1 directly activates #CHEK1, driving #NSCLC growth and EMT, while CHEK1 suppression slows tumour progression, highlighting a promising therapeutic target.

#currentmedicalscience: doi.org/10.1007/s115...